HK1198173A1 - 的强效及選擇性抑制劑 - Google Patents
的强效及選擇性抑制劑Info
- Publication number
- HK1198173A1 HK1198173A1 HK14111760.9A HK14111760A HK1198173A1 HK 1198173 A1 HK1198173 A1 HK 1198173A1 HK 14111760 A HK14111760 A HK 14111760A HK 1198173 A1 HK1198173 A1 HK 1198173A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- nav17
- nav13
- potent
- selective inhibitors
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Insects & Arthropods (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453492P | 2011-03-16 | 2011-03-16 | |
US201261608088P | 2012-03-07 | 2012-03-07 | |
PCT/US2012/029537 WO2012125973A2 (en) | 2011-03-16 | 2012-03-16 | Potent and selective inhibitors of nav1.3 and nav1.7 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198173A1 true HK1198173A1 (zh) | 2015-03-13 |
Family
ID=45895479
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14111760.9A HK1198173A1 (zh) | 2011-03-16 | 2014-11-21 | 的强效及選擇性抑制劑 |
Country Status (23)
Country | Link |
---|---|
US (2) | US9340590B2 (zh) |
EP (1) | EP2686340A2 (zh) |
JP (2) | JP2014509859A (zh) |
KR (1) | KR20140145947A (zh) |
CN (1) | CN103930437A (zh) |
AP (1) | AP2013007173A0 (zh) |
AR (1) | AR088413A1 (zh) |
AU (1) | AU2012228990B2 (zh) |
BR (1) | BR112013023674A2 (zh) |
CA (1) | CA2830065A1 (zh) |
CL (1) | CL2013002673A1 (zh) |
CO (1) | CO6821886A2 (zh) |
CR (1) | CR20130533A (zh) |
EA (1) | EA201391331A1 (zh) |
HK (1) | HK1198173A1 (zh) |
MA (1) | MA35385B1 (zh) |
MX (1) | MX2013010497A (zh) |
PE (1) | PE20140593A1 (zh) |
SG (2) | SG193434A1 (zh) |
TW (1) | TW201300407A (zh) |
UY (1) | UY33959A (zh) |
WO (1) | WO2012125973A2 (zh) |
ZA (1) | ZA201306920B (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9636418B2 (en) | 2013-03-12 | 2017-05-02 | Amgen Inc. | Potent and selective inhibitors of NAV1.7 |
US10344060B2 (en) * | 2013-03-12 | 2019-07-09 | Amgen Inc. | Potent and selective inhibitors of Nav1.7 |
CA2906175C (en) * | 2013-03-15 | 2022-12-13 | Daniel J. Capon | Hybrid immunoglobulin containing non-peptidyl linkage |
LT3116486T (lt) | 2014-03-14 | 2020-04-10 | Biomolecular Holdings Llc | Hibridinis imunoglobulinas, turintis nepetidilinę jungtį |
DK3154561T3 (da) * | 2014-06-12 | 2019-10-07 | Ra Pharmaceuticals Inc | Modulering af komplementaktivitet |
CN105348392B (zh) * | 2015-11-18 | 2019-08-02 | 北京华金瑞清生物医药技术有限公司 | 一种Nav1.7抑制剂及其改造方法 |
US20170239183A1 (en) * | 2016-02-23 | 2017-08-24 | PixarBio Corporation | COMPOSITIONS COMPRISING NAv1.7 SELECTIVE INHIBITORS FOR TREATING ACUTE, POST-OPERATIVE, OR CHRONIC PAIN AND METHODS OF USING THE SAME |
US20190218255A1 (en) * | 2016-09-16 | 2019-07-18 | Olipass Corporation | Scn9a antisense oligonucleotides |
CN110536895B (zh) * | 2017-01-24 | 2023-10-20 | 奥利通公司 | Scn9a反义止痛药 |
CN109517041B (zh) * | 2018-11-14 | 2019-09-17 | 青海芬陀利华生物科技有限公司 | Gptx-1毒素及其应用 |
IL300385A (en) * | 2020-08-05 | 2023-04-01 | Aist | A method for screening for a polypeptide that acts on a target protein |
US20230374084A1 (en) | 2020-09-23 | 2023-11-23 | Aldevron, Llc | Potent and selective inhibitors of nav1.7 |
CN113429463B (zh) * | 2021-05-18 | 2022-08-23 | 湖南百尔泰克生物医药有限公司 | 一种具有镇痛作用的多肽及其应用 |
US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (132)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4351337A (en) | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4083368A (en) | 1976-09-01 | 1978-04-11 | Freezer Winthrop J | Inhaler |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US5002936A (en) | 1985-04-12 | 1991-03-26 | Seymour Lieberman | Lipophilic complexes of pharmacologically active inorganic mineral acid esters of organic compounds |
US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
AU607172B2 (en) | 1986-12-22 | 1991-02-28 | Cygnus, Inc. | Diffusion matrix for transdermal drug administration |
US4906169A (en) | 1986-12-29 | 1990-03-06 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US5023084A (en) | 1986-12-29 | 1991-06-11 | Rutgers, The State University Of New Jersey | Transdermal estrogen/progestin dosage unit, system and process |
US4983395A (en) | 1987-11-12 | 1991-01-08 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4849224A (en) | 1987-11-12 | 1989-07-18 | Theratech Inc. | Device for administering an active agent to the skin or mucosa |
US4847325A (en) | 1988-01-20 | 1989-07-11 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
JP3092811B2 (ja) | 1988-07-23 | 2000-09-25 | デルタ バイオテクノロジー リミテッド | ペプチドおよびdna配列 |
US4925677A (en) | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
US4994439A (en) | 1989-01-19 | 1991-02-19 | California Biotechnology Inc. | Transmembrane formulations for drug administration |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5171264A (en) | 1990-02-28 | 1992-12-15 | Massachusetts Institute Of Technology | Immobilized polyethylene oxide star molecules for bioapplications |
US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
JP3693671B2 (ja) | 1991-03-15 | 2005-09-07 | アムゲン インコーポレーテッド | ポリペプチドのpeg化 |
CA2082951C (en) | 1991-03-15 | 1999-12-21 | Robert M. Platz | Pulmonary administration of granulocyte colony stimulating factor |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
JPH0640945A (ja) | 1992-07-23 | 1994-02-15 | Kureha Chem Ind Co Ltd | Fcフラグメント結合抗腫瘍剤 |
WO1994008599A1 (en) | 1992-10-14 | 1994-04-28 | The Regents Of The University Of Colorado | Ion-pairing of drugs for improved efficacy and delivery |
US5346701A (en) | 1993-02-22 | 1994-09-13 | Theratech, Inc. | Transmucosal delivery of macromolecular drugs |
US5514774A (en) | 1993-06-29 | 1996-05-07 | University Of Utah Research Foundation | Conotoxin peptides |
US5432155A (en) | 1993-06-29 | 1995-07-11 | The Salk Institute For Biological Studies | Conotoxins I |
US5460820B1 (en) | 1993-08-03 | 1999-08-03 | Theratech Inc | Method for providing testosterone and optionally estrogen replacement therapy to women |
US6342225B1 (en) | 1993-08-13 | 2002-01-29 | Deutshces Wollforschungsinstitut | Pharmaceutical active conjugates |
US5919455A (en) | 1993-10-27 | 1999-07-06 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
MX9603570A (es) | 1994-02-23 | 1997-03-29 | Chiron Corp | Metodo y composiciones para incrementar la vida media en suero de agentes farmacologicamente activos. |
FR2717688B1 (fr) | 1994-03-28 | 1996-07-05 | Lhd Lab Hygiene Dietetique | Système matriciel transdermique d'administration d'un oestrogène et/ou un progestatif à base d'EVA. |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
CA2208132A1 (en) | 1994-12-21 | 1996-06-27 | Theratech, Inc. | Transdermal delivery system with adhesive overlay and peel seal disc |
EE9700138A (et) | 1994-12-22 | 1997-12-15 | Astra Aktiebolag | Aerosoolravimvormid |
US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5776896A (en) | 1996-01-03 | 1998-07-07 | Zeneca Limited | Analgesic peptides from venom of grammostola spatulata and use thereof |
US5756663A (en) | 1996-01-03 | 1998-05-26 | Zeneca Limited | Antiarrhythmic peptide from venom of spider Grammostola spatulata |
CA2249195A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
US5783208A (en) | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
AU5369798A (en) | 1996-11-27 | 1998-06-22 | Bachem Bioscience, Inc. | Shk toxin compositions and methods of use |
JP4212651B2 (ja) | 1996-12-26 | 2009-01-21 | サントリー株式会社 | サソリ由来神経ペプチド |
US6548644B1 (en) | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
US5990237A (en) | 1997-05-21 | 1999-11-23 | Shearwater Polymers, Inc. | Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines |
JP3530004B2 (ja) | 1998-02-06 | 2004-05-24 | 株式会社日立ユニシアオートモティブ | 吸入式投薬器 |
US6022952A (en) | 1998-04-01 | 2000-02-08 | University Of Alberta | Compositions and methods for protein secretion |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
AUPP589598A0 (en) | 1998-09-14 | 1998-10-08 | University Of Queensland, The | Novel peptides |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US7029909B1 (en) | 1998-11-20 | 2006-04-18 | Fuso Pharmaceutical Industries, Ltd. | Protein expression vector and utilization thereof |
CN1158068C (zh) | 1998-12-23 | 2004-07-21 | 安姆根有限公司 | 用于缓释蛋白质的多元醇/油悬浮剂 |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
CA2368068A1 (en) | 1999-03-18 | 2000-09-21 | Steven M. Ruben | 27 human secreted proteins |
US6887470B1 (en) | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
WO2001038564A2 (en) | 1999-11-26 | 2001-05-31 | Mcgill University | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
CA2393616A1 (en) | 2000-01-31 | 2001-08-02 | Human Genome Sciences, Inc. | Nucleic acids, proteins, and antibodies |
AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
SE0000935D0 (sv) | 2000-03-21 | 2000-03-21 | Astrazeneca Ab | An inhalation device |
US7125847B1 (en) | 2000-04-07 | 2006-10-24 | The Research Foundation Of State University Of New York At Buffalo | Mechanically activated channel blocker |
CN1133461C (zh) | 2000-04-11 | 2004-01-07 | 厦门北大之路生物工程有限公司 | 虎纹捕鸟蜘蛛毒素提取物在制备镇痛药物中的应用 |
EP1278544A4 (en) | 2000-04-12 | 2004-08-18 | Human Genome Sciences Inc | ALBUMIN FUSION PROTEINS |
EP1280895B1 (en) | 2000-05-10 | 2005-08-03 | Centre National De La Recherche Scientifique (Cnrs) | Polypeptide inhibiting a proton-gated na+ channel |
EP1177806A1 (en) | 2000-08-04 | 2002-02-06 | The Technology Partnership Public Limited Company | Dry powder inhaler |
GB0021617D0 (en) | 2000-09-02 | 2000-10-18 | Imp College Innovations Ltd | Diagnosis and treatment of cancer |
JP5013152B2 (ja) | 2001-02-28 | 2012-08-29 | 株式会社ビーエムジー | 蛋白質複合体形成剤 |
CA2440582A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US7393657B2 (en) | 2001-04-12 | 2008-07-01 | Imperial College Innovations Limited | Diagnosis and treatment of cancer: I |
US20050054051A1 (en) | 2001-04-12 | 2005-03-10 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0120238D0 (en) | 2001-08-20 | 2001-10-10 | Univ College Of London | Sodium channel regulators and modulators |
CN101785861B (zh) | 2001-10-19 | 2014-08-13 | 爱德士实验室公司 | 用于药理活性化合物的可控释放的可注射组合物 |
US6900317B2 (en) | 2002-02-19 | 2005-05-31 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them |
CA2474751A1 (en) | 2002-02-25 | 2003-09-04 | Vanderbilt University | Expression system for human brain-specific voltage-gated sodium channel, type 1 |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
DK2226316T3 (en) | 2002-05-30 | 2016-04-11 | Scripps Research Inst | Copper catalyzed ligation of azides and acetylenes |
GB0219512D0 (en) | 2002-08-21 | 2002-10-02 | Norton Healthcare Ltd | Inhalation compositions with high drug ratios |
WO2004085647A1 (ja) | 2003-03-26 | 2004-10-07 | Pharmadesign, Inc. | イオンチャネルの活性を阻害する低分子ペプチド |
MXPA05013564A (es) | 2003-06-12 | 2006-03-09 | Lilly Co Eli | Proteinas de fusion. |
EP1663994B1 (en) | 2003-08-05 | 2012-03-07 | Vertex Pharmaceuticals Incorporated | Tetrahydroquinazoline compounds as inhibitors of voltage-gated ion channels |
CA2539227A1 (en) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
US7615563B2 (en) | 2003-08-08 | 2009-11-10 | Gonzalez Iii Jesus E | Compositions useful as inhibitors of voltage-gated sodium channels |
US7060723B2 (en) | 2003-08-29 | 2006-06-13 | Allergan, Inc. | Treating neurological disorders using selective antagonists of persistent sodium current |
US7125908B2 (en) | 2003-08-29 | 2006-10-24 | Allergan, Inc. | Treating pain using selective antagonists of persistent sodium current |
JP2007518422A (ja) | 2004-01-21 | 2007-07-12 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | 変異体ナトリウムチャンネルNaν1.7およびそれに関連する方法 |
WO2005118614A1 (en) | 2004-04-08 | 2005-12-15 | Avigen, Inc. | Methods and compositions for treating neuropathic pain |
PL1750683T3 (pl) | 2004-04-23 | 2013-05-31 | Amgen Inc | Formuły o przedłużonym uwalnianiu |
CN1973404B (zh) | 2004-06-23 | 2011-06-08 | 胡贝尔和茹纳股份公司 | 宽带贴片天线 |
GB0414272D0 (en) | 2004-06-25 | 2004-07-28 | Cellpep Sa | OsK1 derivatives |
US7259145B2 (en) | 2004-07-07 | 2007-08-21 | The Research Foundation Of State University Of New York | Mechanically activated channel blocker |
EA011879B1 (ru) | 2004-09-24 | 2009-06-30 | Эмджин Инк. | МОЛЕКУЛЫ С МОДИФИЦИРОВАННЫМ Fc ФРАГМЕНТОМ |
US8080523B2 (en) | 2004-10-07 | 2011-12-20 | The Regents Of The University Of California | Analogs of ShK toxin and their uses in selective inhibition of Kv1.3 potassium channels |
JP2008519034A (ja) | 2004-11-03 | 2008-06-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | イオンチャネル調節剤としてのピリミジン誘導体および使用方法 |
US20060199812A1 (en) | 2005-01-24 | 2006-09-07 | Amgen Inc. | Method of conjugating aminothiol containing molecules to vehicles |
WO2006101629A2 (en) | 2005-02-17 | 2006-09-28 | Vertex Pharmaceuticals Incorporated | SODIUM CHANNEL PROTEIN TYPE III α-SUBUNIT SPLICE VARIANT |
US7833979B2 (en) | 2005-04-22 | 2010-11-16 | Amgen Inc. | Toxin peptide therapeutic agents |
GB0517487D0 (en) | 2005-08-26 | 2005-10-05 | Isis Innovation | Antibodies |
US7972813B2 (en) | 2005-09-30 | 2011-07-05 | Vertex Pharmaceuticals Incorporated | Tetrodotoxin-resistant sodium channel alpha subunit |
KR20140130524A (ko) | 2005-11-08 | 2014-11-10 | 애더리스 래버러토리즈 | Mu-코노톡신 펩티드 및 국소 마취제로서 그의 용도 |
WO2007109324A2 (en) | 2006-03-21 | 2007-09-27 | Xenon Pharmaceuticals, Inc. | Potent and selective nav 1.7 sodium channel blockers |
JP4742345B2 (ja) * | 2006-06-20 | 2011-08-10 | 独立行政法人産業技術総合研究所 | カルシウムチャネルを遮断するグラモストラ・スパチュラタ由来のポリペプチドおよびその遺伝子 |
EP2628749A3 (en) | 2006-06-20 | 2013-12-04 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Antimicrobial kinocidin compostions and methods of use |
US8043829B2 (en) * | 2006-10-25 | 2011-10-25 | Amgen Inc. | DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression |
US8183221B2 (en) | 2007-09-05 | 2012-05-22 | Medtronic, Inc. | Suppression of SCN9A gene expression and/or function for the treatment of pain |
CN101480393A (zh) * | 2008-01-07 | 2009-07-15 | 云南昊邦制药有限公司 | 草乌甲素作为制备治疗Nav1.7疼痛病症药物的应用 |
EP2249856B1 (en) | 2008-01-30 | 2013-11-06 | Baylor College Of Medicine | Peptides that target dorsal root ganglion neurons |
CA2751159A1 (en) | 2009-02-02 | 2010-08-05 | Chromocell Corporation | Cell lines expressing nav and methods of using them |
WO2010104115A1 (ja) * | 2009-03-10 | 2010-09-16 | 独立行政法人産業技術総合研究所 | 膜タンパク質を特異的に認識するポリペプチドの調製方法 |
JP5717143B2 (ja) * | 2009-03-10 | 2015-05-13 | 独立行政法人産業技術総合研究所 | ポリペプチドライブラリーを調製する方法 |
CA2889453C (en) | 2009-03-20 | 2018-11-06 | Amgen Inc. | Carrier immunoglobulins and uses thereof |
BR112012005860A2 (pt) * | 2009-09-15 | 2017-01-31 | Alomone Preclinical Ltd | peptídeos isolados do veneno de aranha, e usos dos mesmos |
GB0922434D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | antibodies and fragments thereof |
GB0922435D0 (en) | 2009-12-22 | 2010-02-03 | Ucb Pharma Sa | Method |
JP6095368B2 (ja) | 2009-10-27 | 2017-03-15 | ユセベ ファルマ ソシエテ アノニム | 機能改変するNav1.7抗体 |
US8871996B2 (en) | 2010-06-09 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Mice expressing human voltage-gated sodium channels |
US9279003B2 (en) | 2010-07-07 | 2016-03-08 | Purdue Pharma L.P. | Analogs of sodium channel peptide toxin |
CN110041420A (zh) | 2012-05-18 | 2019-07-23 | 詹森生物科技公司 | 虎纹捕鸟蛛毒素-iv变体及其使用方法 |
-
2012
- 2012-03-16 CA CA2830065A patent/CA2830065A1/en not_active Abandoned
- 2012-03-16 AP AP2013007173A patent/AP2013007173A0/xx unknown
- 2012-03-16 UY UY0001033959A patent/UY33959A/es not_active Application Discontinuation
- 2012-03-16 SG SG2013068770A patent/SG193434A1/en unknown
- 2012-03-16 TW TW101109226A patent/TW201300407A/zh unknown
- 2012-03-16 EP EP12711312.4A patent/EP2686340A2/en not_active Withdrawn
- 2012-03-16 PE PE2013002050A patent/PE20140593A1/es not_active Application Discontinuation
- 2012-03-16 AU AU2012228990A patent/AU2012228990B2/en active Active
- 2012-03-16 WO PCT/US2012/029537 patent/WO2012125973A2/en active Application Filing
- 2012-03-16 JP JP2013558223A patent/JP2014509859A/ja active Pending
- 2012-03-16 EA EA201391331A patent/EA201391331A1/ru unknown
- 2012-03-16 BR BR112013023674A patent/BR112013023674A2/pt not_active IP Right Cessation
- 2012-03-16 KR KR1020137027301A patent/KR20140145947A/ko not_active Application Discontinuation
- 2012-03-16 SG SG10201601789TA patent/SG10201601789TA/en unknown
- 2012-03-16 MX MX2013010497A patent/MX2013010497A/es unknown
- 2012-03-16 CN CN201280023655.XA patent/CN103930437A/zh active Pending
- 2012-03-16 US US14/005,135 patent/US9340590B2/en active Active
- 2012-03-19 AR ARP120100896A patent/AR088413A1/es unknown
-
2013
- 2013-09-13 ZA ZA2013/06920A patent/ZA201306920B/en unknown
- 2013-09-16 CL CL2013002673A patent/CL2013002673A1/es unknown
- 2013-10-08 MA MA36308A patent/MA35385B1/fr unknown
- 2013-10-11 CO CO13242679A patent/CO6821886A2/es unknown
- 2013-10-16 CR CR20130533A patent/CR20130533A/es unknown
-
2014
- 2014-11-21 HK HK14111760.9A patent/HK1198173A1/zh unknown
-
2016
- 2016-04-20 US US15/134,305 patent/US9796766B2/en active Active
- 2016-08-22 JP JP2016161682A patent/JP2017031157A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MA35385B1 (fr) | 2014-09-01 |
EP2686340A2 (en) | 2014-01-22 |
JP2017031157A (ja) | 2017-02-09 |
KR20140145947A (ko) | 2014-12-24 |
TW201300407A (zh) | 2013-01-01 |
SG193434A1 (en) | 2013-10-30 |
BR112013023674A2 (pt) | 2016-12-13 |
JP2014509859A (ja) | 2014-04-24 |
SG10201601789TA (en) | 2016-04-28 |
US9796766B2 (en) | 2017-10-24 |
PE20140593A1 (es) | 2014-05-10 |
WO2012125973A2 (en) | 2012-09-20 |
CN103930437A (zh) | 2014-07-16 |
US9340590B2 (en) | 2016-05-17 |
EA201391331A1 (ru) | 2014-02-28 |
CR20130533A (es) | 2014-01-09 |
US20140073577A1 (en) | 2014-03-13 |
AR088413A1 (es) | 2014-06-11 |
CA2830065A1 (en) | 2012-09-20 |
ZA201306920B (en) | 2014-05-28 |
AU2012228990A1 (en) | 2013-09-19 |
NZ615242A (en) | 2016-03-31 |
CO6821886A2 (es) | 2013-12-31 |
US20160304570A1 (en) | 2016-10-20 |
WO2012125973A3 (en) | 2013-01-03 |
CL2013002673A1 (es) | 2014-07-25 |
UY33959A (es) | 2012-09-28 |
AP2013007173A0 (en) | 2013-10-31 |
MX2013010497A (es) | 2013-12-16 |
AU2012228990B2 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198173A1 (zh) | 的强效及選擇性抑制劑 | |
HK1246674A1 (zh) | 犬尿氨酸-3-單加氧酶抑制劑、藥物組合物及其使用方法 | |
HK1209737A1 (zh) | 選擇性 δ抑制劑 | |
HK1199726A1 (zh) | 犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法 | |
HK1198827A1 (zh) | 抑制劑及其用途 | |
HK1198619A1 (zh) | 某些犬尿氨酸- -單加氧酶抑制劑、其藥物組合物及其使用方法 | |
EP2782580A4 (en) | SELECTIVE INHIBITORS OF KINASES | |
EP2691797A4 (en) | SYSTEMS AND METHOD OF SORTING FOR DRILLING | |
EP2688901A4 (en) | INHIBITORS OF 17SS-HSD1, 17SS-HSD3 AND 17SS-HSD10 | |
HK1248674B (zh) | 選擇性PI3Kδ抑制劑 |